Webb, P. M. & Jordan, S. J. Global epidemiology of epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 21, 389–400 (2024).
Zhang, Y. et al. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis. BMC Cancer 19, 984 (2019).
Bowtell, D. D. The genesis and evolution of high-grade serous ovarian cancer. Nat. Rev. Cancer 10, 803–808 (2010).
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
Santoro, A. et al. The multiple facets of ovarian high grade serous carcinoma: a review on morphological, immunohistochemical and molecular features. Crit. Rev. Oncol. Hematol. 208, 104603 (2025).
Gaona-Luviano, P., Medina-Gaona, L. A. & Magana-Perez, K. Epidemiology of ovarian cancer. Chin. Clin. Oncol. 9, 47 (2020).
Cabasag, C. J. et al. Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020. Int. J. Cancer 151, 1535–1541 (2022).
Penny, S. M. Ovarian cancer: an overview. Radiol. Technol. 91, 561–575 (2020).
Hong, M. K. & Ding, D. C. Early diagnosis of ovarian cancer: a comprehensive review of the advances, challenges, and future directions. Diagnostics (Basel) 15, 406 (2025).
Elmadani, M. et al. Cancer burden in Europe: a systematic analysis of the GLOBOCAN database (2022). BMC Cancer 25, 447 (2025).
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).
Lheureux, S., Gourley, C., Vergote, I. & Oza, A. M. Epithelial ovarian cancer. Lancet 393, 1240–1253 (2019).
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10–45 (2025).
Madan, E. et al. Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells. Nat. Biotechnol. 43, 1833–1847 (2025).
Menon, U. et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 397, 2182–2193 (2021).
Buys, S. S. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305, 2295–2303 (2011).
Chen, J. et al. Penetrance of breast and ovarian cancer in women who carry a BRCA1/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis. JNCI Cancer Spectr. 4, pkaa029 (2020).
Slade, E., Berg, L., Dworzynski, K., Manchanda, R. & Guideline, C. Ovarian cancer: identifying and managing familial and genetic risk-summary of new NICE guidance. BMJ 385, q807 (2024).
Wei, X. et al. Cost-effectiveness of gene-specific prevention strategies for ovarian and breast cancer. JAMA Netw. Open 7, e2355324 (2024).
Manchanda, R. et al. Risk-reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause: scientific impact paper no. 66 October 2021: scientific impact paper no. 66. BJOG 129, e16–e34 (2022).
Gaba, F. & Manchanda, R. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Best Pract. Res. Clin. Obstet. Gynaecol. 65, 46–65 (2020).
Sideris, M., Menon, U. & Manchanda, R. Screening and prevention of ovarian cancer. Med. J. Aust. 220, 264–274 (2024).
Kuhn, E. et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J. Pathol. 226, 421–426 (2012).
Shih, I. M., Wang, Y. & Wang, T. L. The origin of ovarian cancer species and precancerous landscape. Am. J. Pathol. 191, 26–39 (2021).
Wu, R. C. et al. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. J. Pathol. 248, 41–50 (2019).
Labidi-Galy, S. I. et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 8, 1093 (2017).
Krishnan, R. et al. Spatial transcriptomics characterizes high-grade serous ovarian cancer and its precursor lesions. Gynecol. Oncol. 190, S94–S95 (2024).
Vang, R. & Shih, I. M. Serous tubal intra-epithelial carcinoma: what do we really know at this point?. Histopathology 81, 542–555 (2022).
Luvero, D. et al. Serous tubal intraepithelial carcinoma (STIC): a review of the literature on the incidence at the time of prophylactic surgery. Diagnostics (Basel) 14, 2577 (2024).
Piek, J. M. et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 195, 451–456 (2001).
Meserve, E. E. K. et al. Frequency of ‘incidental’ serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: a six-year study. Gynecol. Oncol. 146, 69–73 (2017).
Samimi, G., Trabert, B., Geczik, A. M., Duggan, M. A. & Sherman, M. E. Population frequency of serous tubal intraepithelial carcinoma (STIC) in clinical practice using SEE-Fim protocol. JNCI Cancer Spectr. 2, pky061 (2018).
Fitzgerald, R. C., Antoniou, A. C., Fruk, L. & Rosenfeld, N. The future of early cancer detection. Nat. Med. 28, 666–677 (2022).
Grandi, G. et al. The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype. Minerva Med. 111, 133–140 (2020).
Zhang, M., Cheng, S., Jin, Y., Zhao, Y. & Wang, Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim. Biophys. Acta Rev. Cancer 1875, 188503 (2021).
Patrono, M. G. et al. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review. Gynecol. Oncol. 139, 568–572 (2015).
Moss, E. L., Hollingworth, J. & Reynolds, T. M. The role of CA125 in clinical practice. J. Clin. Pathol. 58, 308–312 (2005).
Li, J. et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev. Mol. Diagn. 9, 555–566 (2009).
Weinberger, V., Bednarikova, M., Cibula, D. & Zikan, M. Serous tubal intraepithelial carcinoma (STIC)—clinical impact and management. Expert Rev. Anticancer Ther. 16, 1311–1321 (2016).
Hu, D. et al. Evaluation of serum CA125, HE4 and CA724 and the risk of ovarian malignancy algorithm score in the diagnosis of high-grade serous ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 297, 170–175 (2024).
Ishizawa, S. et al. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. J. Natl Cancer Inst. 116, 1798–1806 (2024).
Madan, E. et al. Flower isoforms promote competitive growth in cancer. Nature 572, 260–264 (2019).
Yekelchyk, M. et al. Flower lose, a cell fitness marker, predicts COVID-19 prognosis. EMBO Mol. Med. 13, e13714 (2021).
Rhiner, C. et al. Flower forms an extracellular code that reveals the fitness of a cell to its neighbors in Drosophila. Dev. Cell 18, 985–998 (2010).
Costa-Rodrigues, C., Couceiro, J. & Moreno, E. Cell competition from development to neurodegeneration. Dis. Model Mech. 14, dmm048926 (2021).
Medina, J. E. et al. Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers. Cancer Discov. 15, 105–118 (2025).
Elias, K. M., Guo, J. & Bast, R. C. Jr. Early detection of ovarian cancer. Hematol. Oncol. Clin. North Am. 32, 903–914 (2018).
Nebgen, D. R., Lu, K. H. & Bast, R. C. Jr. Novel approaches to ovarian cancer screening. Curr. Oncol. Rep. 21, 75 (2019).
Kamal, R., Hamed, S., Mansour, S., Mounir, Y. & Abdel Sallam, S. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality. Br. J. Radiol. 91, 20170571 (2018).
Havrilesky, L. J., Sanders, G. D., Kulasingam, S. & Myers, E. R. Reducing ovarian cancer mortality through screening: is it possible, and can we afford it?. Gynecol. Oncol. 111, 179–187 (2008).
Myers, E. R. Reducing ovarian cancer mortality through screening: an impossible dream?. J. Natl Cancer Inst. 116, 1712–1714 (2024).
Englisz, A., Smycz-Kubanska, M. & Mielczarek-Palacz, A. Sensitivity and specificity of selected biomarkers and their combinations in the diagnosis of ovarian cancer. Diagnostics (Basel) 14, 949 (2024).
Hada, A. et al. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses. J. Ovarian Res. 13, 46 (2020).
Lof, P. et al. Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?. Gynecol. Oncol. 166, 284–291 (2022).
Welsh, J. B. et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl Acad. Sci. USA 98, 1176–1181 (2001).
Schummer, M. et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238, 375–385 (1999).
Chen, F., Shen, J., Wang, J., Cai, P. & Huang, Y. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag. Res. 10, 1313–1318 (2018).
Nyangoh-Timoh, K., Bendifallah, S., Dion, L., Ouldamer, L. & Leveque, J. Borderline ovarian tumours: CNGOF guidelines for clinical practice—value of tumor markers. Gynecol. Obstet. Fertil. Senol. 48, 277–286 (2020).
Reilly, G. et al. Analytical validation of a deep neural network algorithm for the detection of ovarian cancer. JCO Clin. Cancer Inform. 6, e2100192 (2022).
Alanbay, I. et al. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor. Gynecol. Endocrinol. 28, 478–482 (2012).
Brown, D. L. et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology 208, 103–110 (1998).
Li, G. et al. Transformer-based AI technology improves early ovarian cancer diagnosis using cfDNA methylation markers. Cell Rep. Med. 5, 101666 (2024).
Trinidad, C. V. et al. Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer. Sci. Rep. 13, 18341 (2023).
De Santiago, P. R. et al. LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker. NPJ Precis. Oncol. 9, 62 (2025).
Bast, R. C. Jr. et al. Biomarkers and strategies for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 29, 2504–2512 (2020).
Simmons, A. R. et al. Complementary longitudinal serum biomarkers to CA125 for early detection of ovarian cancer. Cancer Prev. Res. (Phila.) 12, 391–400 (2019).
Yang, W. L. et al. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Cancer 126, 725–736 (2020).
Guo, J. et al. Osteopontin, macrophage migration inhibitory factor and anti-Interleukin-8 autoantibodies complement CA125 for detection of early stage ovarian cancer. Cancers (Basel) 11, 596 (2019).
Muinao, T., Deka Boruah, H. P. & Pal, M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon 5, e02826 (2019).
Yang, W. L. et al. Elevation of TP53 autoantibody before CA125 in preclinical invasive epithelial ovarian cancer. Clin. Cancer Res. 23, 5912–5922 (2017).
Moss, E. et al. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: recommendations for practice update 2024. Eur. J. Obstet. Gynecol. Reprod. Biol. 300, 69–123 (2024).
Menon, U. et al. Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. Lancet Oncol. 24, 1018–1028 (2023).
Bedia, J. S. et al. Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS. EBioMedicine 112, 105554 (2025).
National Cancer Audit Collaborating Centre. Welcome to the National Ovarian Cancer Audit (NOCA). https://ckan.publishing.service.gov.uk/dataset/national-ovarian-cancer-audit-state-of-the-nation-report-2025 (2025; accessed 18 October 2025).
Steenbeek, M. P. et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis. J. Clin. Oncol. 40, 1879–1891 (2022).
Kotnik, E. N. et al. Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival. Commun. Biol. 6, 688 (2023).
Kim, J. et al. Cell origins of high-grade serous ovarian cancer. Cancers (Basel) 10, 433 (2018).
Barnes, B. M. et al. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med. 13, 140 (2021).
Bodelon, C. et al. Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity. Clin. Cancer Res. 25, 5937–5946 (2019).
Dochez, V. et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J. Ovarian Res. 12, 28 (2019).
Wang, Q. Y., Feng, X. L., Liu, X. F. & Zhu, S. Y. Prognostic value of elevated pre-treatment serum CA-125 in epithelial ovarian cancer: a meta-analysis. Front. Oncol. 12, 868061 (2022).
Funston, G. et al. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: a population-based cohort study. PLoS Med. 17, e1003295 (2020).
Balachandran, A. & Nayak, S. R. An observational study of factors affecting CA125 levels in premenopausal women. Adv. Biomed. Res. 12, 235 (2023).
Duffy, M. J. et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int. J. Gynecol. Cancer 15, 679–691 (2005).
Crawford, S. M. & Evans, C. Outcome of elevated CA125 values from primary care following implementation of ovarian cancer guidelines. Fam. Pract. 35, 199–202 (2018).
Zhang, R., Siu, M. K. Y., Ngan, H. Y. S. & Chan, K. K. L. Molecular biomarkers for the early detection of ovarian cancer. Int. J. Mol. Sci. 23, 12041 (2022).
Kim, S. H. & Weigelt, B. Circulating cell-free (cf)DNA analysis: current technologies and applications in gynecologic cancer. Gynecol. Oncol. Rep. 54, 101431 (2024).
Mohr, A. E., Ortega-Santos, C. P., Whisner, C. M., Klein-Seetharaman, J. & Jasbi, P. Navigating challenges and opportunities in multi-omics integration for personalized healthcare. Biomedicines 12, 1496 (2024).
Mattox, A. K. et al. The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer. Cancer Discov. 13, 2166–2179 (2023).
National Cancer Institute. SEER*Explorer: an interactive website for SEER cancer statistics. Surveillance Research Program. https://seer.cancer.gov/statistics-network/explorer/ (2025; accessed 22 July 2025).
National Cancer Institute. SEER Cancer Stat Facts: Ovarian Cancer. https://seer.cancer.gov/statfacts/html/ovary.html (2024; accessed 22 July 2025).
Sabelli, R. et al. The challenge of managing isolated STIC lesions: a single-center experience. Gynecol. Oncol. Rep. 58, 101716 (2025).
Pepe, M. S., Feng, Z., Janes, H., Bossuyt, P. M. & Potter, J. D. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl Cancer Inst. 100, 1432–1438 (2008).
Philpott, S. et al. The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2. J. Med. Genet. 60, 440–449 (2023).
Rosenthal, A. N. et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study. J. Clin. Oncol. 35, 1411–1420 (2017).
Dagan, E. & Shochat, T. Quality of life in asymptomatic BRCA1/2 mutation carriers. Prev. Med. 48, 193–196 (2009).
Chandrasekaran, D. et al. Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study. Cancers (Basel) 13, 4344 (2021).
Leung, E. Y. et al. British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom. Int. J. Gynecol. Cancer. 34, 1334–1343 (2024).
Manchanda, R. et al. Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. J. Natl Compr. Canc. Netw. 22, e237331 (2024).
Sun, L. et al. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol. 5, 1718–1730 (2019).
Sun, L. et al. Cost-effectiveness of genetic testing for all women diagnosed with breast cancer in China. Cancers (Basel) 14, 1839 (2022).
Torr, B. et al. BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial. Br. J. Cancer 131, 1506–1515 (2024).
Manchanda, R. et al. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes. BJOG 127, 364–375 (2020).
Manchanda, R. & Sideris, M. Population-based genetic testing for cancer susceptibility genes: quo vadis?. BJOG 130, 125–130 (2023).
Manchanda, R. et al. Economic evaluation of population-based BRCA1/BRCA2 mutation testing across multiple countries and health systems. Cancers (Basel) 12, 1929 (2020).
Sun, L. et al. Economic evaluation of population-based BRCA1 and BRCA2 testing in Canada. JAMA Netw. Open 7, e2432725 (2024).
Torr, B. et al. The NHS England Jewish BRCA Testing Programme: overview after first year of implementation (2023-2024). J. Med. Genet. 62, 69–73 (2025).
Venkatesan, P. BRCA testing launched for people of Jewish ancestry in England. Lancet Oncol. 25, 284 (2024).
Greenberg, R. et al. Carrier screening program for BRCA1/BRCA2 pathogenic variants among Ashkenazi Jewish women in Israel: an observational study. Genet. Med. Open 1, 100824 (2023).
NHS—Health Research Authority. PROTECT-C: population based germline testing for early detection and prevention of cancer. https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/protect-c_v10/ (2025; accessed 5 August 2025).
Gart, J. J. & Nam, J. Approximate interval estimation of the ratio of binomial parameters: a review and corrections for skewness. Biometrics 44, 323–338 (1988).
Zhang, D., Wang, J., Cai, S. & Surtihadi, J. Skewness-corrected confidence intervals for predictive values in enrichment studies. Stat. Med. 43, 5862–5871 (2024).
Bu, J. et al. An avidity-based PD-L1 antagonist using nanoparticle-antibody conjugates for enhanced immunotherapy. Nano Lett. 20, 4901–4909 (2020).
Nair, A. et al. Hybrid nanoparticle system integrating tumor-derived exosomes and poly(amidoamine) dendrimers: implications for an effective gene delivery platform. Chem. Mater. 35, 3138–3150 (2023).
Mamidi, N. & Delgadillo, R. M. V. Design, fabrication and drug release potential of dual stimuli-responsive composite hydrogel nanoparticle interfaces. Colloids Surf. B Biointerfaces 204, 111819 (2021).
Sun, Z., Nyberg, R., Wu, Y., Bernard, B. & Redmond, W. L. Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers. PLoS ONE 16, e0247238 (2021).
Erwied, P. et al. Optimized workflow of EV enrichment from human plasma samples for downstream mass spectrometry analysis. Discov. Oncol. 15, 374 (2024).
Pinheiro, C. et al. Identification and validation of extracellular vesicle reference genes for the normalization of RT–qPCR data. J. Extracell. Vesicles 13, e12421 (2024).
R Core Team R: A Language and Environment for Statistical Computing (R Core Team, 2026).
Eklund, A. & Trimble, J. beeswarm: The bee swarm plot, an alternative to stripchart. R Package version 0.4.0. CRAN https://CRAN.R-project.org/package=beeswarm (2021).
Robin, X. et al. pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).
DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–845 (1988).
Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32–35 (1950).
Clopper, C. J. & Pearson, E. S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26, 404–413 (1934).
Wilhelm, J. Supporting data and reproducibility code for ‘blood-based RNA biomarker for the early detection of ovarian cancer’ (version 1.0) (data set). Zenodo https://doi.org/10.5281/zenodo.23016074 (2026).
